National Center for Research Resources; Notice of Closed Meeting, 10981 [06-1972]
Download as PDF
Federal Register / Vol. 71, No. 42 / Friday, March 3, 2006 / Notices
wwhite on PROD1PC61 with NOTICES
in the prevention of gene silencing and
replication delay.
Claims are directed to specific
constructs and methods of using
replicators and transgene constructs to
inhibit, delay or prevent gene silencing
and are available for licensing. The
addition of these sequences to nonreplicating or self-replicating gene
delivery systems may be key in the
development of effective gene delivery
vectors.
Related portfolios available for
licensing include: (1) the Mammalian
Artificial Chromosome Portfolio [HHS
Ref. No. E–128–2005/0–US–01, U.S.
Provisional Patent Application No. 60/
669,589 filed 08 Apr 2005 and HHS Ref.
No. E–253–2000/0–US–03, U.S. Patent
Application Publication No. U.S. 2004/
0245317 filed 08 Apr 2002) and (2) the
TAR Cloning Portfolio (HHS Ref. No. E–
121–1996/0–US–06 and HHS Ref. No.
E–158–2001/0–US–02, U.S. Patent
Application Publication No. U.S. 2004/
0248289 filed 04 Oct 2002].
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
TNF-alpha Converting Enzyme
Inhibitory Agents and Stimulatory
Agents
Stewart J. Levine et al. (NHLBI).
U.S. Provisional Application No. 60/
505,394 filed 24 Sep 2003 (HHS
Reference No. E–208–2003/0–US–01);
PCT Application No. PCT/US2004/
031608 filed 24 Sep 2004, which
published as WO 2005/030798 on 07
Apr 2005 (HHS Reference No. E–208–
2003/0–PCT–02).
Licensing Contact: Marlene Astor; 301/
435–4426; shinnm@mail.nih.gov.
The action of Tumor Necrosis Factor
alpha (TNF-alpha) has been implicated
in such diseases as arthritis, sepsis,
ulcerative colitis, multiple sclerosis,
Crohn’s disease, septic shock, graft
rejection, cachexia, insulin resistance,
post-ischemic reperfusion injury, tumor
metastasis, tissue ulceration, abnormal
wound healing, periodontal disease,
bone disease, proteinuria, aneurismal
aortic disease, degenerative cartilage
loss, demyelinating diseases of the
nervous system, and HIV infection.
TNF-alpha converting enzyme (TACE)
or ADAM 17 (A Disintegrin And
Metalloprotease) is a member of a family
of zinc metalloproteases, and is an
important regulator of inflammation,
immune regulation, and cellular
proliferation as a consequence of its
ability to catalyze the activation of TNFalpha from a membrane bound to a
soluble form.
VerDate Aug<31>2005
16:43 Mar 02, 2006
Jkt 208001
The NIH announces the identification
of a protein, corresponding to the
amino-terminus of the TACE
prodomain, that possesses a TACE
inhibitory activity that is independent
of a cysteine-switch mechanism. This
TACE inhibitory protein could be used
as a new therapeutic agent against
chronic inflammatory diseases that are
mediated by TNF-alpha.
Dated: January 21, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–3013 Filed 3–2–06; 8:45 am]
BILLING CODE 4167–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
SEPA Review.
Date: March 14–15, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Hilton, 620 Perry
Parkway, Gaithersburg, MD 20877.
Contact Person: Bonnie Dunn, PhD,
Scientific Review Administrator, Office of
Review, National Center for Research
Resources, National Institutes of Health, 6705
Democracy Blvd., Dem. 1, Room 1074, MSC
4874, Bethesda, MD 20892–4874, (301) 435–
0824, dunnbo@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333, National Institutes of Health,
HHS)
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
10981
Dated: February 24, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–1971 Filed 3–2–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel,
Biotechnology SEP.
Date: March 2–3, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Steven Birken, PhD,
Scientific Review Administrator, National
Institutes of Health, National Center for
Research Resources, Office of Review, 6701
Democracy Blvd., 1 Democracy Plaza, Room
1078, Bethesda, MD 20892, (301) 435–0815,
birkens@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333, National Institutes of Health,
HHS)
Dated: February 24, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–1972 Filed 3–2–06; 8:45am]
BILLING CODE 4140–01–M
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 71, Number 42 (Friday, March 3, 2006)]
[Notices]
[Page 10981]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1972]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Research Resources; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Research Resources
Special Emphasis Panel, Biotechnology SEP.
Date: March 2-3, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Steven Birken, PhD, Scientific Review
Administrator, National Institutes of Health, National Center for
Research Resources, Office of Review, 6701 Democracy Blvd., 1
Democracy Plaza, Room 1078, Bethesda, MD 20892, (301) 435-0815,
birkens@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure, 93.306, 93.333,
National Institutes of Health, HHS)
Dated: February 24, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-1972 Filed 3-2-06; 8:45am]
BILLING CODE 4140-01-M